Clinical utility of labeled cells for detection of allograft rejection and myocardial infarction

Noninvasive detection of rejection of transplanted hearts with indium-111-labeled lymphocytes

To determine whether cardiac transplant rejection can be detected noninvasively with indium-111 (111In)-labeled lymphocytes, we studied 11 dogs with thoracic heterotopic cardiac transplants without immunosuppression and five dogs with transplants treated with cyclosporine (10 mg/kg/day) and prednisone (1 mg/kg/day). All were evaluated sequentially with gamma scintigraphy after administration of 150 to 350 muCi of autologous 111In-lymphocytes. Technetium-99m-labeled red blood cells (1 to 3 mCi) were used for correction of radioactivity in the blood pool attributable to circulating labeled lymphocytes. Lymphocyte infiltration was quantified as the ratio of indium in the myocardium of the transplant or native heart compared with that in blood (indium excess, IE). Results were correlated with mechanical and electrical activity of allografts and with histologic findings in sequential biopsy specimens. In untreated dogs (n = 11), IE was 15.5 +/- 7.0 (SD) in transplanted hearts undergoing rejection and 0.4 +/- 1.1 in native hearts on the day before animals were killed (p less than .01). In dogs treated with cyclosporine and prednisone (n = 5), IE was minimal in allografts during the course of immunosuppression (0.8 +/- 0.4) and increased to 22.9 +/- 11.1 after immunosuppression was stopped. Scintigraphic criteria of rejection (IE greater than 2 SD above that in native hearts) correlated with results of biopsies indicative of rejection and appeared before electrophysiologic or mechanical manifestations of dysfunction. Thus infiltration of labeled lymphocytes in allografts, indicative of rejection, is detectable noninvasively by gamma scintigraphy and provides a sensitive approach potentially applicable to clinical monitoring for early detection of rejection and guidance for titration of immunosuppressive measures.

Radiolabeled blood cells: techniques and applications

During the past few years, the clinical and experimental applications of autologous blood cells labeled with gamma-emitting radionuclides, i.e., technetium-99m (Tc-99m) and indium-111 (In-111) have continued to grow rapidly. Investigations have centered around developing techniques that would label blood cells efficiently without alteration of cell viability and their pathophysiologic integrity. Experimental and clinical applications have been aimed at the studies of in vivo cell kinetics and detecting abnormal lesions by external imaging. These will be discussed in detail together with their advantages and disadvantages, and the future directions will be outlined.